A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

NCT07356453 · clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
40
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

FoRx Therapeutics AG